WO2024252327A8 - Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4r)-n- {(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates - Google Patents

Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4r)-n- {(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates Download PDF

Info

Publication number
WO2024252327A8
WO2024252327A8 PCT/IB2024/055548 IB2024055548W WO2024252327A8 WO 2024252327 A8 WO2024252327 A8 WO 2024252327A8 IB 2024055548 W IB2024055548 W IB 2024055548W WO 2024252327 A8 WO2024252327 A8 WO 2024252327A8
Authority
WO
WIPO (PCT)
Prior art keywords
solid forms
ethyl
prolinamide
oxopyrrolidin
valyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2024/055548
Other languages
English (en)
Other versions
WO2024252327A1 (fr
Inventor
Kapildev Kashmirilal ARORA
Maria GONZALEZ ESGUEVILLAS
Samir Kulkarni
Aifang Li
Paul Anthony MEENAN
Nandini PATEL
Jeanene Elizabeth Tickner
Xiaojing Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to EP24733330.5A priority Critical patent/EP4724423A1/fr
Priority to AU2024285970A priority patent/AU2024285970A1/en
Priority to MX2025014633A priority patent/MX2025014633A/es
Priority to KR1020267000360A priority patent/KR20260021033A/ko
Priority to CN202480038170.0A priority patent/CN121311467A/zh
Publication of WO2024252327A1 publication Critical patent/WO2024252327A1/fr
Publication of WO2024252327A8 publication Critical patent/WO2024252327A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne des formes solides de N-(méthoxycarbonyl)-3-méthyl-L-valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-L-prolinamide, I, telles que des formes anhydres, une forme amorphe, un solvate de cyclopentyle éther méthylique, un solvate d'acétate d'isopropyle, et un solvate d'acétate d'éthyle de celui-ci de formule (I) ainsi que des compositions pharmaceutiques comprenant les formes solides et des méthodes de traitement utilisant les formes solides.
PCT/IB2024/055548 2023-06-09 2024-06-06 Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4r)-n- {(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates Ceased WO2024252327A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP24733330.5A EP4724423A1 (fr) 2023-06-09 2024-06-06 Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4 r)- n- {(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates
AU2024285970A AU2024285970A1 (en) 2023-06-09 2024-06-06 Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4r)- n-{(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
MX2025014633A MX2025014633A (es) 2023-06-09 2024-06-06 Formas solidas de n-(metoxicarbonil)-3-metil-l-valil-(4r)-n-{(1s)-1-ciano-2-[(3s)-2-oxopirrolidin-3-il]etil}-4-(trifluorometil)-l-prolinamida y solvatos de la misma
KR1020267000360A KR20260021033A (ko) 2023-06-09 2024-06-06 N-(메톡시카보닐)-3-메틸-l-발릴-(4r)-n-｛(1s)-1-시아노-2-[(3s)-2-옥소피롤리딘-3-일]에틸｝-4-(트리플루오로메틸)-l-프롤린아미드의고체 형태 및 이의 용매화물
CN202480038170.0A CN121311467A (zh) 2023-06-09 2024-06-06 N-(甲氧羰基)-3-甲基-l-缬氨酰基-(4r)-n-{(1s)-1-氰基-2-[(3s)-2-氧代吡咯烷-3-基]乙基}-4-(三氟甲基)-l-脯氨酰胺及其溶剂化物的固体形式

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363507347P 2023-06-09 2023-06-09
US63/507,347 2023-06-09
US202463647157P 2024-05-14 2024-05-14
US63/647,157 2024-05-14

Publications (2)

Publication Number Publication Date
WO2024252327A1 WO2024252327A1 (fr) 2024-12-12
WO2024252327A8 true WO2024252327A8 (fr) 2025-06-26

Family

ID=91581111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055548 Ceased WO2024252327A1 (fr) 2023-06-09 2024-06-06 Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4r)-n- {(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates

Country Status (6)

Country Link
EP (1) EP4724423A1 (fr)
KR (1) KR20260021033A (fr)
CN (1) CN121311467A (fr)
AU (1) AU2024285970A1 (fr)
MX (1) MX2025014633A (fr)
WO (1) WO2024252327A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP6419313B2 (ja) 2014-05-09 2018-11-07 キネタ・インコーポレイテッドＫｉｎｅｔａ， Ｉｎｃ． 抗ウイルスの化合物、医薬組成物およびその使用方法
CN112617981A (zh) 2019-09-24 2021-04-09 广州迪克医疗器械有限公司 穿刺杆及穿刺器
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Also Published As

Publication number Publication date
CN121311467A (zh) 2026-01-09
MX2025014633A (es) 2026-02-03
WO2024252327A1 (fr) 2024-12-12
TW202513557A (zh) 2025-04-01
EP4724423A1 (fr) 2026-04-15
AU2024285970A1 (en) 2025-12-11
KR20260021033A (ko) 2026-02-12

Similar Documents

Publication Publication Date Title
RU2424240C2 (ru) Антибактериальные производные пиперидина
EA199800290A1 (ru) (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2
AU2003292437A1 (en) Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors
RU95101430A (ru) Производные 1-бифенилметилимидазола, их получение, фармацевтическая композиция, способ лечения или профилактики гипертонии
FI950309A0 (fi) Proliiniamidijohdannaisia
ES2120070T3 (es) Esteres nitricos dotados de una actividad anti-inflamatoria y/o analgesica y su procedimiento de preparacion.
BR0206637A (pt) Processo para preparação de atorvastatina em forma não cristalina e de formulação farmacêutica
AU2001280438A1 (en) Substituted heterocyclic amides
CY1119188T1 (el) Αντιμικροβιακα συντηρητικα για την επιτευξη φαρμακοτεχνικης μορφης πολλαπλης δοσης χρησιμοποιωντας βητα-κυκλοεξτρινες για υγρες μορφες δοσολογιας
AU5910996A (en) Pyrrole derivatives and medicinal composition
DE602004019049D1 (de) Stabile feste medizinische zusammensetzung für die orale verabreichung von ramosetron
BR0111678A (pt) Composições medicinais contendo derivados de propenona
NO912511D0 (no) Fremgangsmaate for forhindring eller begrensning av reperfusjonsskade
WO2024252327A8 (fr) Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4r)-n- {(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates
EA200200108A1 (ru) Производные стрептограминов, способ их получения и композиции на их основе
ATE138389T1 (de) Gellanester
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
EP0806421A4 (fr) Derives de l'acide quiloleine carboxylique
KR960700229A (ko) 콜레시스토키닌 및 가스트린-관련된 장애의 치료 및 예방을 위한 n-아실피롤리딘 및 약제(n-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders)
CA2202904A1 (fr) Composition preventive et remede pour les maladies allergiques de type i
FI943799A0 (fi) Fenoksifenyylisyklopentenyylihydroksiureoita
AR076772A1 (es) Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe
HK40129817A (zh) N-(甲氧羰基)-3-甲基-l-缬氨酰基-(4r)-n-{(1s)-1-氰基-2-[(3s)-2-氧代吡咯烷-3-基]乙基}-4-(三氟甲基)-l-脯氨酰胺及其溶剂化物的固体形式
CA2266363A1 (fr) Inhibiteur de turbidite sous-epitheliale
CA3294775A1 (fr) Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4r)-n- {(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24733330

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 827537

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: AU2024285970

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 827537

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 202517121896

Country of ref document: IN

Ref document number: MX/A/2025/014633

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2025571171

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025571171

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: P2025-03955

Country of ref document: AE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026134

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2024285970

Country of ref document: AU

Date of ref document: 20240606

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 202517121896

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 1020267000360

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: 1020267000360

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2024733330

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024733330

Country of ref document: EP

Effective date: 20260109

WWE Wipo information: entry into national phase

Ref document number: 2025134554

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2024733330

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024733330

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024733330

Country of ref document: EP

Effective date: 20260109

WWP Wipo information: published in national office

Ref document number: MX/A/2025/014633

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024733330

Country of ref document: EP

Effective date: 20260109

WWP Wipo information: published in national office

Ref document number: 1020267000360

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2025134554

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2024733330

Country of ref document: EP